Latest Blog Posts Tagged "Non-Motor Symptoms"
February 10, 2017
MJFF funded early research of this novel drug candidate, mGluR4, helping remove financial and other barriers to advance its testing.
February 09, 2017
Pharmaceutical company Acorda reported positive results from a Phase III trial of an inhaled form of levodopa to treat "off" periods in Parkinson's.
January 10, 2017
The FDA recently agreed to review the New Drug Application for a dyskinesia medication developed by Adamas Pharmaceuticals.
September 01, 2016
In the last few months, Cynapsus Therapeutics Inc. has announced Phase II results of its under-the-tongue strip to alleviate motor symptoms, FDA Fast Track Designation and a buyout.
April 14, 2016
MJFF's Dr. Brian Fiske discusses how we may be able to target treatments to the "type" of Parkinson's one has, much like is done in cancer care.
December 28, 2015
Adamas has announced positive Phase III results for its treatment for dyskinesia, involuntary movements that are a side effect of levodopa use. Such a therapy could impact how we treat motor symptoms.
September 04, 2015
Acadia Pharmaceuticals announced this week that it has submitted a New Drug Application to the FDA seeking approval for its drug to treat psychosis associated with Parkinson's disease.
June 26, 2015
MJFF staff share news from the 19th International Congress of Parkinson's Disease and Movement Disorders last week in San Diego.
June 16, 2015
The U.S. Food and Drug Administration announced Friday that it had approved another deep brain stimulation device for treatment of Parkinson's disease and essential tremor.
May 06, 2015
Dr. Rachel Dolhun tells Practical Neurology about recently approved levodopa formulations that may help avoid wearing off and dyskinesia.